Verification of WFA-Sialylated MUC1 as a Sensitive Biliary Biomarker for Human Biliary Tract Cancer

Takayuki Yamaguchi, Yukihiro Yokoyama, Tomoki Ebata, Atsushi Matsuda, Atsushi Kuno, Yuzuru Ikehara, Junichi Shoda, Hisashi Narimatsu, Masato Nagino

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: The diagnostic accuracy of biliary cytology is limited. A novel sandwich enzyme-linked immunosorbent assay that combined Wisteria floribunda agglutinin (WFA) and anti-sialylated mucin 1 (MUC1) monoclonal antibody to target bile samples was recently developed. This study was designed to verify the diagnostic accuracy of WFA-sialylated MUC1 as a sensitive biliary biomarker for human biliary tract cancer. Methods: Bile samples from 27 patients with benign disease and 174 patients with biliary tract cancer were analyzed. A receiver-operated characteristic curve analysis for biliary WFA-sialylated MUC1 and serum CA19-9 levels was performed to determine the cutoff value for the prediction of the presence of biliary tract cancer. Results: Biliary WFA-sialylated MUC1 levels were significantly higher in the biliary tract cancer group compared with the benign group (P < 0.001). The cutoff value of WFA-sialylated MUC1 for discriminating biliary tract cancer was 10.5. The sensitivity of WFA-sialylated MUC1 in discriminating biliary tract cancer was much higher (82.2 %) than that of cytology (23.6 %) when this cutoff value was used. The cutoff value of serum CA19-9 for discriminating biliary tract cancer was 38 IU/L in the same cohort. All patients with biliary WFA-sialylated MUC1 and serum CA19-9 above the cutoff values had biliary tract cancer, and no patient with benign disease was categorized in this group. Conclusions: Biliary WFA-sialylated MUC1 is a useful biomarker for the differentiation of biliary tract cancer. The sensitivity of WFA-sialylated MUC1 was clearly higher than that of biliary cytology. Further data collection is necessary to validate the clinical usefulness of this biomarker.

Original languageEnglish
Pages (from-to)671-677
Number of pages7
JournalAnnals of Surgical Oncology
Volume23
Issue number2
DOIs
Publication statusPublished - 2016 Feb 1
Externally publishedYes

Fingerprint

Biliary Tract Neoplasms
Mucin-1
Biomarkers
Cell Biology
Bile
Serum
wisteria lectin
Enzyme-Linked Immunosorbent Assay
Monoclonal Antibodies

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Verification of WFA-Sialylated MUC1 as a Sensitive Biliary Biomarker for Human Biliary Tract Cancer. / Yamaguchi, Takayuki; Yokoyama, Yukihiro; Ebata, Tomoki; Matsuda, Atsushi; Kuno, Atsushi; Ikehara, Yuzuru; Shoda, Junichi; Narimatsu, Hisashi; Nagino, Masato.

In: Annals of Surgical Oncology, Vol. 23, No. 2, 01.02.2016, p. 671-677.

Research output: Contribution to journalArticle

Yamaguchi, T, Yokoyama, Y, Ebata, T, Matsuda, A, Kuno, A, Ikehara, Y, Shoda, J, Narimatsu, H & Nagino, M 2016, 'Verification of WFA-Sialylated MUC1 as a Sensitive Biliary Biomarker for Human Biliary Tract Cancer', Annals of Surgical Oncology, vol. 23, no. 2, pp. 671-677. https://doi.org/10.1245/s10434-015-4878-4
Yamaguchi, Takayuki ; Yokoyama, Yukihiro ; Ebata, Tomoki ; Matsuda, Atsushi ; Kuno, Atsushi ; Ikehara, Yuzuru ; Shoda, Junichi ; Narimatsu, Hisashi ; Nagino, Masato. / Verification of WFA-Sialylated MUC1 as a Sensitive Biliary Biomarker for Human Biliary Tract Cancer. In: Annals of Surgical Oncology. 2016 ; Vol. 23, No. 2. pp. 671-677.
@article{c4c02987a51940938a9ec9fbfafe58cf,
title = "Verification of WFA-Sialylated MUC1 as a Sensitive Biliary Biomarker for Human Biliary Tract Cancer",
abstract = "Background: The diagnostic accuracy of biliary cytology is limited. A novel sandwich enzyme-linked immunosorbent assay that combined Wisteria floribunda agglutinin (WFA) and anti-sialylated mucin 1 (MUC1) monoclonal antibody to target bile samples was recently developed. This study was designed to verify the diagnostic accuracy of WFA-sialylated MUC1 as a sensitive biliary biomarker for human biliary tract cancer. Methods: Bile samples from 27 patients with benign disease and 174 patients with biliary tract cancer were analyzed. A receiver-operated characteristic curve analysis for biliary WFA-sialylated MUC1 and serum CA19-9 levels was performed to determine the cutoff value for the prediction of the presence of biliary tract cancer. Results: Biliary WFA-sialylated MUC1 levels were significantly higher in the biliary tract cancer group compared with the benign group (P < 0.001). The cutoff value of WFA-sialylated MUC1 for discriminating biliary tract cancer was 10.5. The sensitivity of WFA-sialylated MUC1 in discriminating biliary tract cancer was much higher (82.2 {\%}) than that of cytology (23.6 {\%}) when this cutoff value was used. The cutoff value of serum CA19-9 for discriminating biliary tract cancer was 38 IU/L in the same cohort. All patients with biliary WFA-sialylated MUC1 and serum CA19-9 above the cutoff values had biliary tract cancer, and no patient with benign disease was categorized in this group. Conclusions: Biliary WFA-sialylated MUC1 is a useful biomarker for the differentiation of biliary tract cancer. The sensitivity of WFA-sialylated MUC1 was clearly higher than that of biliary cytology. Further data collection is necessary to validate the clinical usefulness of this biomarker.",
author = "Takayuki Yamaguchi and Yukihiro Yokoyama and Tomoki Ebata and Atsushi Matsuda and Atsushi Kuno and Yuzuru Ikehara and Junichi Shoda and Hisashi Narimatsu and Masato Nagino",
year = "2016",
month = "2",
day = "1",
doi = "10.1245/s10434-015-4878-4",
language = "English",
volume = "23",
pages = "671--677",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Verification of WFA-Sialylated MUC1 as a Sensitive Biliary Biomarker for Human Biliary Tract Cancer

AU - Yamaguchi, Takayuki

AU - Yokoyama, Yukihiro

AU - Ebata, Tomoki

AU - Matsuda, Atsushi

AU - Kuno, Atsushi

AU - Ikehara, Yuzuru

AU - Shoda, Junichi

AU - Narimatsu, Hisashi

AU - Nagino, Masato

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Background: The diagnostic accuracy of biliary cytology is limited. A novel sandwich enzyme-linked immunosorbent assay that combined Wisteria floribunda agglutinin (WFA) and anti-sialylated mucin 1 (MUC1) monoclonal antibody to target bile samples was recently developed. This study was designed to verify the diagnostic accuracy of WFA-sialylated MUC1 as a sensitive biliary biomarker for human biliary tract cancer. Methods: Bile samples from 27 patients with benign disease and 174 patients with biliary tract cancer were analyzed. A receiver-operated characteristic curve analysis for biliary WFA-sialylated MUC1 and serum CA19-9 levels was performed to determine the cutoff value for the prediction of the presence of biliary tract cancer. Results: Biliary WFA-sialylated MUC1 levels were significantly higher in the biliary tract cancer group compared with the benign group (P < 0.001). The cutoff value of WFA-sialylated MUC1 for discriminating biliary tract cancer was 10.5. The sensitivity of WFA-sialylated MUC1 in discriminating biliary tract cancer was much higher (82.2 %) than that of cytology (23.6 %) when this cutoff value was used. The cutoff value of serum CA19-9 for discriminating biliary tract cancer was 38 IU/L in the same cohort. All patients with biliary WFA-sialylated MUC1 and serum CA19-9 above the cutoff values had biliary tract cancer, and no patient with benign disease was categorized in this group. Conclusions: Biliary WFA-sialylated MUC1 is a useful biomarker for the differentiation of biliary tract cancer. The sensitivity of WFA-sialylated MUC1 was clearly higher than that of biliary cytology. Further data collection is necessary to validate the clinical usefulness of this biomarker.

AB - Background: The diagnostic accuracy of biliary cytology is limited. A novel sandwich enzyme-linked immunosorbent assay that combined Wisteria floribunda agglutinin (WFA) and anti-sialylated mucin 1 (MUC1) monoclonal antibody to target bile samples was recently developed. This study was designed to verify the diagnostic accuracy of WFA-sialylated MUC1 as a sensitive biliary biomarker for human biliary tract cancer. Methods: Bile samples from 27 patients with benign disease and 174 patients with biliary tract cancer were analyzed. A receiver-operated characteristic curve analysis for biliary WFA-sialylated MUC1 and serum CA19-9 levels was performed to determine the cutoff value for the prediction of the presence of biliary tract cancer. Results: Biliary WFA-sialylated MUC1 levels were significantly higher in the biliary tract cancer group compared with the benign group (P < 0.001). The cutoff value of WFA-sialylated MUC1 for discriminating biliary tract cancer was 10.5. The sensitivity of WFA-sialylated MUC1 in discriminating biliary tract cancer was much higher (82.2 %) than that of cytology (23.6 %) when this cutoff value was used. The cutoff value of serum CA19-9 for discriminating biliary tract cancer was 38 IU/L in the same cohort. All patients with biliary WFA-sialylated MUC1 and serum CA19-9 above the cutoff values had biliary tract cancer, and no patient with benign disease was categorized in this group. Conclusions: Biliary WFA-sialylated MUC1 is a useful biomarker for the differentiation of biliary tract cancer. The sensitivity of WFA-sialylated MUC1 was clearly higher than that of biliary cytology. Further data collection is necessary to validate the clinical usefulness of this biomarker.

UR - http://www.scopus.com/inward/record.url?scp=84958173637&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958173637&partnerID=8YFLogxK

U2 - 10.1245/s10434-015-4878-4

DO - 10.1245/s10434-015-4878-4

M3 - Article

C2 - 26416714

AN - SCOPUS:84958173637

VL - 23

SP - 671

EP - 677

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 2

ER -